Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 1/2022

03-03-2022 | Obesity | Review article

Metabolic syndrome and underlying genetic determinants-A systematic review

Authors: Sanjeev Rana, Shafat Ali, Hilal Ahmad Wani, Qazi Danish Mushtaq, Swarkar Sharma, Muneeb U Rehman

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2022

Login to get access

Abstract

The metabolic syndrome is a cluster of heritable and related traits which has been associated with a range of pathophysiological factors including dyslipidaemia, abdominal obesity, increased fasting plasma glucose (FPG) and hypertension. The documented genetic basis of the metabolic syndrome include several chromosomal positions, numerous candidate gene-associated polymorphisms, different genetic variants, which are linked to the syndrome either as a trait or entities mainly linked to metabolic process. Additionally, the latest findings related to the contribution of epigenetic mechanisms, microRNAs, sporadic variants, non-coding RNAs, and assessing the role of genes in molecular systems has enhanced our understanding of the syndrome. Considerable work has been done to understand the underlying disease mechanisms by elucidating its genetic etiology. Nonetheless, a common shared genetic cause has not been established to clarify the coexistence of their components and further investigation is required. While mostly neglected and rarely known, hereditary predisposition needs to be studied, including with the current defective phenotypic condition descriptions. Metabolic syndrome is a multi-faceted characteristic with abundant properties and the condition can arise from interactions between environmental variables such as physical inactivity, caloric obesity and genetic susceptibility. Although there is support for genetic determinants from family and twin research, there is still no recognised genomic DNA marker for genetic association and linkages with quite a long way off potential for clinical application. In the present review efforts have been made to through light on the various genetic determinants with large effects that underlie with the association of these traits to this syndrome. The heterogeneity and multifactorial heritability of MetS, however, has been a challenge towards understanding the factors underlying the association of these traits.
Literature
1.
Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Smith SC Jr. Joint scientific statement. Circulation. 2009;120:1640–5.PubMedCrossRef
2.
Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WPT, Loria CM, Smith SC Jr, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef
3.
4.
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics—2020 update: A report from the American Heart Association. Circulation. 2020;141:e139–596.PubMedCrossRef
5.
Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Raso FUM, Muiesan ML, Ryliškytė L, Rietzschel E, et al. Metabolic syndrome across Europe: Different clusters of risk factors. Eur J Prev Cardiol. 2015;22:486–91.PubMedCrossRef
6.
Sygnowska E, Piwońska A, Waśkiewicz A, Broda G. Socioeconomic factors and the risk of metabolic syndrome in the adult Polish population: The WOBASZ study. Kardiol Pol. 2012;70:718–27.PubMed
7.
8.
Suliga E, Kozieł D, Cieśla E, Rebak D, Głuszek S. Dietary patterns in relation to metabolic syndrome among adults in Poland: A Cross-sectional study. Nutrients. 2017;9:1366.PubMedCentralCrossRef
9.
Kant AK, Graubard BI. 40-year trends in meal and snack eating behaviors of American adults. J Acad Nutr Diet. 2015;115:50–63.PubMedCrossRef
10.
Riou J, Lefevre T, Parizot I, Lhuissier A, Chauvin P. Is there still a French eating model? A taxonomy of eating behaviors in adults living in the Paris metropolitan area in 2010. PLoS ONE. 2015;10:e0119161.PubMedPubMedCentralCrossRef
11.
Gupta NJ, Kumar V, Panda S. A camera-phone based study reveals erratic eating pattern and disrupted daily eating-fasting cycle among adults in India. PLoS ONE. 2017;12:e0172852.PubMedPubMedCentralCrossRef
12.
Gill S, Panda S. A Smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits. Cell Metab. 2015;22:789–98.PubMedPubMedCentralCrossRef
13.
Chow LS, Manoogian ENC, Alvear A, Fleischer JG, Thor H, Dietsche K, Wang Q, Hodges JS, Esch N, Malaeb S, et al. Time-restricted eating effects on body composition and metabolic measures in humans who are overweight: A feasibility study. Obesity. 2020;28:860–9.PubMedCrossRef
14.
Zarrinpar A, Chaix A, Panda S. Daily eating patterns and their impact on health and disease. Trends Endocrinol Metab. 2016;27:69–83.PubMedCrossRef
15.
Cahill LE, Chiuve SE, Mekary RA, Jensen MK, Flint AJ, Hu FB, Rimm EB. Prospective study of breakfast eating and incident coronary heart disease in a cohort of male US health professionals. Circulation. 2013;128:337–43.PubMedPubMedCentralCrossRef
16.
Pot GK, Almoosawi S, Stephen AM. Meal irregularity and cardiometabolic consequences: Results from observational and intervention studies. Proc Nutr Soc. 2016;75:475–86.PubMedCrossRef
17.
Ha K, Song Y. Associations of meal timing and frequency with obesity and metabolic syndrome among Korean adults. Nutrients. 2019;11:2437.PubMedCentralCrossRef
18.
Suliga E, Cieśla E, Rębak D, Kozieł D, Głuszek S. Relationship between sitting time, physical activity, and metabolic syndrome among adults depending on body mass index (BMI). Med Sci Monit. 2018;24:7633–45.PubMedPubMedCentralCrossRef
19.
Sperling LC, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MRG, et al. The CardioMetabolic Health Alliance. Working toward a new care model for the metabolic syndrome. Am Coll Cardiol. 2015;66:1050–67.CrossRef
20.
Vera B, Dashti HS, Gómez-Abellán P, Hernández AM, Esteban A, Scheer FAJL, Saxena R, Garaulet M. Modifiable lifestyle behaviors, but not a genetic risk score, associate with metabolic syndrome in evening chronotypes. Sci Rep. 2018;8:945.PubMedPubMedCentralCrossRef
21.
Pérez-Martínez P, Mikhailidis DP, Athyros VG, Bullo M, Couture P, Covas MI, de Koning L, Delgado-Lista J, Díaz-López A, Drevon CA, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation. Nutr Rev. 2017;75:307–26.PubMedPubMedCentralCrossRef
22.
Heymsfield SB, Harp JB, Reitman ML, Beetsch JW, Schoeller DA, Erondu N, Pietrobelli A. Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. Am J Clin Nutr. 2007;85:346–54.PubMedCrossRef
23.
Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, et al. Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. Nutrition. 2015;31:1–13.PubMedCrossRef
24.
Fallaize R, Carvalho-Wells AL, Tierney AC, Marin C, Kieć-Wilk B, Dembińska-Kieć A, et al. APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome. Sci Rep. 2017;7:6274.PubMedPubMedCentralCrossRef
25.
Rodriguez-Nunez I, Caluag T, Kirby K, Rudick CN, Dziarski R, Gupta D. Nod2 and Nod2-regulated microbiota protect BALB/c mice from diet-induced obesity and metabolic dysfunction. Sci Rep. 2017;7(1):548.PubMedPubMedCentralCrossRef
26.
Wang H, Dong S, Xu H, Qian J, Yang J. Genetic variants in FTO associated with metabolic syndrome: a meta- and gene-based analysis. Mol Biol Rep. 2012;39(5):5691–8.PubMedCrossRef
27.
Stančáková A, Laakso M. Genetics of metabolic syndrome. Rev Endocr Metab Disord. 2014;15(4):243–52.PubMedCrossRef
28.
Milagro FI, Gomez-Abellan P, Campion J, Martinez JA, Ordovas JM, Garaulet M. CLOCK, PER2 and BMAL1 DNA methylation: association with obesity and metabolic syndrome characteristics and monounsaturated fat intake. Chronobiol Int. 2012;29(9):1180–94.
29.
Hosoki K, Ogata T, Kagami M, Tanaka T, Saitoh S. Epimutation (hypomethylation) affecting the chromosome 14q32.2 imprinted region in a girl with upd(14)mat-like phenotype. European Journal of Human Genetics : EJHG. 2008;16(8):1019–23.PubMedCrossRef
30.
Zhang Y, Kent JW 2nd, Lee A, Cerjak D, Ali O, et al. Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population. BMC Med Genomics. 2013;6:9.
31.
32.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.PubMedCrossRef
33.
Lahiry P, Pollex RL, Hegele RA. Uncloaking the genetic determinants of metabolic syndrome. J Nutrigenet Nutrigenomics. 2008;1(3):118–25.PubMed
34.
Falkner B, Cossrow ND. Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States. Curr Hypertens Rep. 2014;16(7):449.PubMedPubMedCentralCrossRef
35.
Berenjy S, Rahmat AB, Hanachi P, Sunn LM, Yassin ZB, Sahebjamee F. Metabolic Syndrome in Iran, Global. J Health Sci. 2010;2(2):117–22.
36.
37.
Song QB, Zhao Y, Liu YQ, Zhang J, Xin SJ, Dong GH. Sex difference in the prevalence of metabolic syndrome and cardiovascular-related risk factors in urban adults from 33 communities of China: the CHPSNE study. Diabe-tes Vasc Dis Res. 2015;12(3):189–98.CrossRef
38.
39.
40.
41.
Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageno W, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol. 2009;29(3):311–5.PubMedCrossRef
42.
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21–8.PubMedCrossRef
43.
Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018;40(2):215–24.PubMedCrossRef
44.
45.
Shen Z, Wang X, Zhen Z, Wang Y, Sun P. Metabolic syndrome components and acute pancreatitis: a case–control study in China. BMC Gastroenterol. 2021;21(1):1–8.CrossRef
46.
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–78.PubMedCrossRef
47.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.PubMedCrossRef
48.
49.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef
50.
Alberti KG, et al. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.PubMedCrossRef
51.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–3.PubMedCrossRef
52.
Einhorn D, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–52.PubMedCrossRef
53.
54.
55.
Szewczyk-Golec K, Woźniak A, Reiter RA. Inter-relationship of the chronobiotic, melatonin, with leptin and adiponectin: Implications for obesity. J Pineal Res. 2015;59:277–91.PubMedCrossRef
56.
Szewczyk-Golec K, Rajewski P, Gackowski M, Mila-Kierzenkowska C, Wesołowski R, Sutkowy P, Pawłowska M, Woźniak A. Melatonin supplementation lowers oxidative stress and regulates adipokines in obese patients on a calorie-restricted diet. Oxid Med Cell Longev. 2017;2017:8494107.PubMedPubMedCentralCrossRef
57.
Qian J, Morris CJ, Caputo R, Garaulet M, Scheer FAJL. Ghrelin is impacted by the endogenous circadian system and by circadian misalignment in humans. Int J Obes. 2019;43:1644–9.CrossRef
58.
Garaulet M, Qian J, Florez JC, Arendt J, Saxena R, Scheer FAJL. Melatonin effects on glucose metabolism: Time to unlock the controversy. Trends Endocrinol Metab. 2020;31:192–204.PubMedPubMedCentralCrossRef
59.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.PubMedCrossRef
60.
61.
Rutter M, Meigs JB, Sullivan LM, D’Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the framingham offspring study. Circulation. 2004;110:380–5.PubMedCrossRef
62.
Robertsa CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705–12.CrossRef
63.
Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care. 2002;25:2016–21.PubMedCrossRef
64.
Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation. 2003;108:414–9.PubMedCrossRef
65.
Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care. 2005;28:690–3.PubMedCrossRef
66.
Swiatkiewicz I, Taub PR. The usefulness of C-reactive protein for the prediction of post-infarct left ventricular systolic dysfunction and heart failure. Kardiol Pol. 2018;76:821–9.PubMedCrossRef
67.
Swiatkiewicz I, Magielski P, Kubica A, Zadourian A, DeMaria AN, Taub PR. Enhanced inflammation is a marker for risk of post-infarct ventricular dysfunction and heart failure. Int J Mol Sci. 2020;21:807.PubMedCentralCrossRef
68.
Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes. 2004;28:674–9.CrossRef
69.
Aronson D, Sella R, Sheikh-Ahmad M, Kerner A, Avizohar O, Rispler S, Bartha P, Markiewicz W, Levy Y, Brook GJ. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol. 2004;44:2003–7.PubMedCrossRef
70.
Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440:944–8.PubMedCrossRef
71.
Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50:567–75.PubMedCrossRef
72.
Rania V, Deepb G, Singhc RK, Palled K, Yadav UCS. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.CrossRef
73.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.PubMedCrossRef
74.
Kahn R, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:1684–99.PubMedCrossRef
75.
Stern MP, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676–81.PubMedCrossRef
76.
Greenland P, O’Malley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med. 2005;165:2454–6.PubMedCrossRef
77.
Lawlor DA, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005;90:5677–83.PubMedCrossRef
78.
Hegele RA, Pollex RL. Genetic and physiological insights into the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol. 2005;289:R663–9.PubMedCrossRef
79.
Sutton BS, et al. Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Hum Genet. 2005;117:107–18.PubMedCrossRef
80.
Jeunemaitre X, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169–80.PubMedCrossRef
81.
Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37:268–85.PubMedPubMedCentral
82.
Waterworth DM, et al. Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol. 2000;20:2663–9.PubMedCrossRef
83.
Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res. 2002;10:1078–86.PubMedCrossRef
84.
Kondo H, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 2002;51:2325–8.PubMedCrossRef
85.
Ohashi K, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004;43:1195–200.PubMedCrossRef
86.
Siffert W, et al. Association of a human G-protein β3 subunit variant with hypertension. Nat Genet. 1998;18:45–8.PubMedCrossRef
87.
Siffert W, et al. Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol. 1999;10:1921–30.PubMedCrossRef
88.
Ridderstrale M, et al. FOXC2 mRNA expression and a 5’ untranslated region polymorphism of the gene are associated with insulin resistance. Diabetes. 2002;51:3554–60.PubMedCrossRef
89.
Kotzka J, Muller-Wieland D. Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Ther Targets. 2004;8:141–9.PubMedCrossRef
90.
Lin H-F, Boden-Albala B, Juo S, Park N, Rundek T, Sacco R. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia. 2005;48(10):2006–12.PubMedPubMedCentralCrossRef
91.
Sookoian S, Pirola CJ. Metabolic syndrome: from the genetics to the pathophysiology. Curr Hypertens Rep. 2011;13(2):149–57.PubMedCrossRef
92.
Carmelli D, et al. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments? Am J Hum Genet. 1994;55:566–73.PubMedPubMedCentral
93.
Edwards KL, et al. Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol. 1997;14:241–53.PubMedCrossRef
94.
Austin MA, et al. Heritability of multivariate factors of the metabolic syndrome in nondiabetic Japanese americans. Diabetes. 2004;53:1166–9.PubMedCrossRef
95.
Chen W, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study. Atherosclerosis. 1999;145:197–205.PubMedCrossRef
96.
Lee KE, et al. Familial aggregation of components of the multiple metabolic syndrome in the Framingham Heart and Offspring Cohorts: Genetic Analysis Workshop Problem 1. BMC Genet. 2003;4(Suppl 1):S94.PubMedPubMedCentralCrossRef
97.
Wu KD, et al. Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study. Hypertens Res. 2002;25:529–36.PubMedCrossRef
98.
Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigantype familial partial lipodystrophy. Hum Mol Genet. 2000;9:109–12.PubMedCrossRef
99.
Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation. 2001;103:2225–9.PubMedCrossRef
100.
Kissebah AH, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA. 2000;97:14478–83.PubMedPubMedCentralCrossRef
101.
Arya R, et al. Factors of insulin resistance syndrome—related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans. Diabetes. 2002;51:841–7.PubMedCrossRef
102.
Loos RJ, et al. Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study. J Clin Endocrinol Metab. 2003;88:5935–43.PubMedCrossRef
103.
Langefeld CD, et al. Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study. Diabetes. 2004;53:1170–4.PubMedCrossRef
104.
Pollex RL, Hegele RA. Complex trait locus linkage mapping in atherosclerosis: time to take a step back before moving forward? Arterioscler Thromb Vasc Biol. 2005;25:1541–4.PubMedCrossRef
105.
Ambye L, et al. Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract. 2005;67:175–9.PubMedCrossRef
106.
Andersen G, et al. Studies of the association of the GNB3 825C → T polymorphism with components of the metabolic syndrome in white Danes. Diabetologia. 2005;49:75–82.PubMedCrossRef
107.
Bing C, et al. Large-scale studies of the Leu72Met polymorphism of the ghrelin gene in relation to the metabolic syndrome and associated quantitative traits. Diabet Med. 2005;22:1157–60.PubMedCrossRef
108.
Costa LA, et al. The ACE insertion/deletion polymorphism is not associated with the metabolic syndrome (WHO Definition) in Brazilian type 2 diabetic patients. Diabetes Care. 2002;25:2365–6.PubMedCrossRef
109.
Dallongeville J, et al. The Gly16 → Arg16 and Gln27 → Glu27 polymorphisms of β2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab. 2003;88:4862–6.PubMedCrossRef
110.
Erkkila AT, et al. Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease. Nutr Metab Cardiovasc Dis. 2002;12:53–9.PubMed
111.
Fernandez ML, et al. Association of NOS3 gene with metabolic syndrome in hypertensive patients. Thromb Haemost. 2004;92:413–48.PubMedCrossRef
112.
Frederiksen L, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-γ gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002;87:3989–92.PubMed
113.
Frederiksen L, et al. No interactions between polymorphisms in the β3-adrenergic receptor gene and the PPAR-γ gene on the risk of the insulin resistance syndrome in the Danish MONICA cohort. Diabetologia. 2003;46:729–31.PubMedCrossRef
114.
Guettier JM, et al. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab. 2005;90:1705–11.PubMedCrossRef
115.
Hamid YH, et al. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia. 2005;48:251–60.PubMedCrossRef
116.
Hamid YH, et al. The common T60N polymorphism of the lymphotoxin-alpha gene is associated with type 2 diabetes and other phenotypes of the metabolic syndrome. Diabetologia. 2005;48:445–51.PubMedCrossRef
117.
Lee YJ, Tsai JC. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care. 2002;25:1002–8.PubMedCrossRef
118.
McCarthy JJ, et al. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet. 2003;114:87–98.PubMedCrossRef
119.
Meirhaeghe A, et al. Association between peroxisome proliferator-activated receptor γ haplotypes and the metabolic syndrome in French men and women. Diabetes. 2005;54:3043–8.PubMedCrossRef
120.
Meirhaeghe A, et al. Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol Genet Metab. 2005;86:293–9.PubMedCrossRef
121.
Pollex RL, et al. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis. 2006;184:121–9.PubMedCrossRef
122.
Rhee EJ, et al. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-γ gene on metabolic syndrome. Arch Med Res. 2006;37:86–94.PubMedCrossRef
123.
Robitaille J, et al. Association between the PPARα-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49:482–9.PubMedCrossRef
124.
Steinle NI, et al. Variation in the lamin A/C gene: associations with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:1708–13.PubMedCrossRef
125.
Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: a systematic review, Obesity reviews : an official journal of the International Association for the Study of. Obesity. 2011;12(11):952–67.
126.
F.V. do Nascimento, V. Piccoli, M.A. Beer, A.D. von Frankenberg, D. Crispim, F. Gerchman, Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review, Diabetology & metabolic syndrome 7 (2015) 38
127.
Zhou JM, Zhang M, Wang S, Wang BY, Han CY, Ren YC, et al. Association of the ADIPOQ Rs2241766 and Rs266729 Polymorphisms with Metabolic Syndrome in the Chinese Population: A Metaanalysis. Biomedical and environmental sciences : BES. 2016;29(7):505–15.PubMed
128.
Hegele RA, et al. Genetic variation in LMNA modulates plasma leptin and indices of obesity in aboriginal Canadians. Physiol Genomics. 2000;3:39–44.PubMedCrossRef
129.
Hegele RA, et al. Common genomic variation in LMNA modulates indexes of obesity in Inuit. J Clin Endocrinol Metab. 2001;86:2747–51.PubMed
130.
131.
132.
Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002;22:1058–61.PubMedCrossRef
Metadata
Title
Metabolic syndrome and underlying genetic determinants-A systematic review
Authors
Sanjeev Rana
Shafat Ali
Hilal Ahmad Wani
Qazi Danish Mushtaq
Swarkar Sharma
Muneeb U Rehman
Publication date
03-03-2022
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2022
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-022-01009-z

Other articles of this Issue 1/2022

Journal of Diabetes & Metabolic Disorders 1/2022 Go to the issue

Research article

Relationship between depression and psychological well-being among persons with diabetes during COVID-19 pandemic: diabetes distress as a mediator

Research article

Use of haematological signatures in conjunction with conventional biomarkers to assess Reno-protective effects of Gedunin in diabetic nephropathy of Streptozotocin induced diabetic rats

Research article

Body awareness mediates the relationship between body mass index and lipid profiles in adolescents

Review article

Evaluation of the Risk Factors for Type 2 Diabetes Using the Generalized Structure Equation Modeling in Iranian Adults based on Shahedieh Cohort Study

Research article

Investigation of expression of myocardial miR-126, miR-29a and miR-222 as a potential marker in STZ- induced diabetic rats following interval and continuous exercise training

Research article

Association between dietary patterns and body composition in normal-weight subjects with metabolic syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits